Journal Basic Info

  • Impact Factor: 1.995**
  • H-Index: 8
  • ISSN: 2474-1647
  • DOI: 10.25107/2474-1647
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Thoracic Surgery
  •  Obstetrics Surgery
  •  Breast Surgery
  •  Transplant Surgery
  •  Robotic Surgery
  •  Cardiovascular Surgery
  •  Minimally Invasive Surgery
  •  Pediatric Surgery

Abstract

Citation: Clin Surg. 2021;6(1):3212.Research Article | Open Access

A Prospective Study on the Role of Centchroman in Regression of Fibroadenoma

Navdeep Kumar Singla , Ruby Bhatia , Renu Verma and Suresh Kumar Bhatia

Department of General Surgery, GMC Patiala, Punjab, India Department of Obstetrics and Gynecology, GMC Patiala, Punjab, India

*Correspondance to: Renu Verma 

 PDF  Full Text DOI: 10.25107/2474-1647.3212

Abstract

Fibroadenoma commonly present as painless breast lump in young girls. Nearly 10% to 15% regress spontaneously over the period of 6 to 60 months, rest are managed surgically. Centchroman (Saheli), a novel non-steroidal, selective anti-estrogen has been used for the treatment of mastalgia and its effectiveness in the treatment of fibroadenoma is being tested in the ongoing trials. Patients and Methods: We studied the role of Centchroman in regression of fibroadenoma. A total of 60 patients between 15 to 35 years of age with painless lump breast of size 2 cm to 5 cm confirmed as fibroadenoma by FNAC were included in the study. Detailed patient?s characteristics, clinical history, physical examination (for size in 2 dimensions), ultrasound findings (for size in 3 dimensions) were assessed. All participants included in the study were given tablet Centchroman (Saheli) 30 mg thrice weekly orally for 3 months. Size of Fibroadenoma was reassessed clinically for size in two dimensions and ultrasonologically for size in three dimensions at 4 weeks and 3 months of starting of therapy. Conclusion: Out of 60 patients, 18 patients (30%) had complete response, 40 patients (66.66%) showed a decrease in the size of fibroadenoma and only 2 patients (3.33%) had no response to this therapy. None showed an increase in size. It may prove to be the most effective modality for the treatment of small sized fibroadenoma breast especially in unmarried girls with minimal side effects. Ultrasonology may be relied upon for follow up measurements since it is more accurate in measuring the dimensions.

Keywords

Fibroadenoma; Centchroman; Saheli; Non-steroidal; Anti-estrogen; Ultrasonology

Cite the article

Singla NK, Bhatia R, Verma R, Bhatia SK. A Prospective Study on the Role of Centchroman in Regression of Fibroadenoma. Clin Surg. 2021; 6: 3212..

Search Our Journal

Journal Indexed In

Articles in PubMed

Voice Outcomes in Laryngotracheal Stenosis: Impact of the Montgomery T-tube
 PubMed  PMC  PDF  Full Text
Sildenafil Transiently Delays Early Alveolar Bone Healing of Tooth Extraction Sockets
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Experimental Occipital Lobe Epilepsy in Cats: A Possible Model of Photic Epilepsy
 Abstract  PDF  Full Text
Prevalence and Clinical Characteristics of Autoimmune Gastritis in Patients with Severe Atrophic Gastritis
 Abstract  PDF  Full Text
View More...